Eli Lilly (LLY) Income from Continuing Operations (2009 - 2026)

Eli Lilly (LLY) has reported Income from Continuing Operations for 18 consecutive years, with 7396000000.0 the latest figure, recorded in Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 7396000000.0, up 168.07% year-over-year; the trailing twelve-month figure through Mar 2026 was 25276700000.0 (up 127.59% YoY), and the FY2025 annual result was 20640000000.0, up 94.9% from the prior year.
• Income from Continuing Operations was 7396000000.0 for Q1 2026 at Eli Lilly, up from 6637700000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 7396000000.0 in Q1 2026 and troughed at 57400000.0 in Q3 2023.
• Average Income from Continuing Operations over 5 years is 2947676470.59, with a median of 2189300000.0 recorded in 2023.
• Year-over-year, Income from Continuing Operations tumbled 103.95% in 2023 and jumped 1790.42% in 2024.
• Over 5 years, Income from Continuing Operations stood at 1937700000.0 in 2022, then rose by 12.98% to 2189300000.0 in 2023, then surged by 101.43% to 4409800000.0 in 2024, then jumped by 50.52% to 6637700000.0 in 2025, then advanced by 11.42% to 7396000000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 7396000000.0 in Q1 2026, 6637700000.0 in Q4 2025, and 5582500000.0 in Q3 2025.